The regulator agreed to allow Sangamo Therapeutics to use data to seek accelerated approval for its Fabry gene therapy ...

Sangamo's phase 1/2 STARR study data using isaralgagene civaparvovec targeting patients with Fabry Disease is expected in H1 2025. Learn more on SGMO stock here.

The biotech engaged with the FDA on alternative pathways to approval after seeing safety and efficacy data from the phase 1/2 ...

Shares in Sangamo Therapeutics (Nasdaq: SGMO) surged around 40% on Tuesday, following the announcement that the US Food and ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares are moving higher Tuesday after the company announced the FDA approved an ...

Sangamo (SGMO) announced the outcome of a recent interaction with the FDA, providing a clear regulatory pathway to accelerated approval for ...

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) and keeping the ...

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 ...

HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company pioneering CRISPR-based programmable genome medicines, today announced the appointment of Dr. TJ Cradick as Chief ...

There has been a gene therapy on the market for people with the bleeding disorder haemophilia A since 2022, but take-up has been very slow. Pfizer and Sangamo are hoping for a faster trajectory ...

Year-to-date, Sangamo Therapeutics has shown a stellar performance, with a YTD gain of +144.28%. In comparison, the S&P 500 has delivered a more modest +22.23% gain in the same timeframe. This stark ...

Sangamo will shift its development focus to genome engineering as the field and science mature. “Gene therapy can ultimately only take you into the liver,” he explains. “There are 7,000 ...